Tomorrow’s Trade Idea, Today
ALIGNED WITH THE BULLS
Braces for the Call
Barclays $BCS ( ▲ 1.59% ) upgraded Align Technology $ALGN ( ▲ 3.94% ) to Overweight. Analyst Glen Santangelo set a price target of $200.
Shares had reached $197 in early February following strong fourth-quarter results and fiscal 2026 guidance. But the broader war-driven market pullback swept them lower.
Santangelo sees that as an opening.
War, Worry, and 10x EBITDA
The core argument is valuation. At 10x EBITDA, Santangelo believes ALGN is well-positioned to benefit once the conflict eases.
He acknowledged the uncertainty plainly. "If the conflict drags on, our call may prove to be premature," he wrote. But the underlying data gave him conviction.
Fourth-quarter results showed momentum spread evenly across market segments and geographies. Website traffic to Align's homepage and its My Invisalign page suggests the trend has carried into the current quarter.
That matters because consensus has modeled a 2.4% sequential revenue decline from Q4 to Q1. Yet, Align's revenue exposure to the Middle East is in the single digits.
The Straight Story
The analyst community is largely, well, aligned.
Of 18 ratings on ALGN, 11 are Buy or Strong Buy. Six are Hold. One is Underperform. No analysts rate the stock a Sell.
Still, shares are in the red since the February peak. Santangelo is betting the pullback has more to do with headlines than fundamentals.
